Alto Neuroscience, a clinical-stage biopharmaceutical company focused on neuropsychiatric disorders, has secured $120 million from institutional and accredited investors to advance ALTO-207, a fixed-dose combination targeting treatment-resistant depression. ALTO-207 is a novel therapy for treatment-resistant…
Don't miss
The non-fungible token ($NFT) market has recorded a dynamic week in terms of activity. In this respect, the…
Ethereum Coin Holds the Line While the broader cryptocurrency market has shown signs of renewed vigor, Ethereum ($ETH)…
Wall Street has spent months debating when the Federal Reserve will cut interest rates. Now, traders are considering…
The latest supply event from Chainlink is back in focus as the network completed its routine quarterly unlock,…
Disclaimer: This is not investment advice. The information provided is for general purposes only. No information, materials, services…
Ethereum has surged roughly 36% from its recent accumulation zone, pushing the price into a critical area where…